What is the share price of Jiangsu Hengrui medicine?

Written by Editorial Team | Last Updated: August 2026

The share price of Jiangsu Hengrui Pharmaceuticals Co., Ltd. (traded on the Shanghai Stock Exchange under the stock code 600276) is approximately 53.00 CNY. Jiangsu Hengrui is a leading research-based pharmaceutical enterprise in China focusing on anti-tumor drugs, surgical medicines, and contrast agents. Its equity valuation responds to clinical research trial outcomes, National Reimbursement Drug List inclusions, research and development spending levels, intellectual property pipelines, and overarching trends influencing the Chinese pharmaceutical manufacturing sector.

Related FAQs

Pfizer completed the total divestment of its remaining equity position in Haleon plc, fully exiting its former consumer healthcare joint venture.

Berkshire Hathaway Class A stands as the most expensive stock in the United States when measured by individual per-share cost, trading consistently at hundreds of thousands of dollars per single share. Other prominent U.S.

Yes, China Mobile is a dividend-paying company. It has a well-established history of distributing profits to its shareholders, currently offering a dividend yield that is consistently covered by its corporate earnings.

The global pharmaceutical sector is anchored by massive, highly capitalized biopharmaceutical corporations that drive innovative drug discovery, oncology treatments, and blockbuster therapies.

China functions as a dominant global manufacturing hub for active pharmaceutical ingredients, generic chemical compounds, and intermediate raw components used by pharmaceutical industries worldwide.

Jiangsu Hengrui Medicine Co., Ltd., alongside major biopharmaceutical innovators like Sinopharm and Shanghai Fosun Pharmaceutical, is widely recognized as one of the largest and most influential domestic pharmaceutical companies in China.

Apple Inc. and Microsoft Corporation alternate as the richest publicly traded companies in the world by market capitalization, frequently valued above $3 trillion USD.

Meliá Hotels International operates properties across a diverse spectrum of tiers, encompassing upscale and luxury segments rather than exclusively luxury classifications.

Jiangsu Hengrui Pharmaceuticals Company Ltd., often known as Hengrui Pharma, is the largest listed pharmaceutical company in China.

Yes, China plays an essential role in the production of pharmaceuticals for the U.S. market, serving as the world's largest supplier of Active Pharmaceutical Ingredients (APIs). These APIs are the fundamental substances that make a drug effective.

China's powerhouse economy relies on massive industrial sectors that drive domestic output, international trade, and global manufacturing supply chains.

Public equity markets feature ultra-large-cap corporations whose immense market valuations reflect global economic dominance across technology, energy, and digital services.

Not all ibuprofen is manufactured in China, as global pharmaceutical production of this essential nonsteroidal anti-inflammatory drug spans multiple countries, including India, the United States, and several European nations.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Older adults experience altered pharmacokinetics and pharmacodynamics, making them highly susceptible to adverse drug reactions, toxicity, and cognitive impairment from certain classes of medications outlined in clinical guidelines like the Beers Cri...

A substantial portion of the world's raw active pharmaceutical ingredients utilized to manufacture generic ibuprofen originates in chemical manufacturing hubs located across China and India.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

The current worth of a given share depends entirely on the specific company or security you are evaluating, ranging from a few dollars for small-cap equities to hundreds or thousands of dollars for major technology and industrial giants.

The aggregate market capitalization of the United States stock market substantially exceeds that of China, driven by the massive concentration of mega-cap global technology enterprises, deep institutional capital pools, and extensive international in...

Jiangsu Hengrui Pharmaceuticals Co., Ltd. holds a massive multi-billion-dollar market capitalization when converted into U.S. dollars, reflecting its standing as a premier pharmaceutical and biotechnology enterprise in China.

Public health studies and epidemiological surveillance in China identify chronic non-communicable disorders and major metabolic conditions as the primary drivers of morbidity and mortality.